P21 vs MOTS-c
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
P21
P21 is a synthetic peptide derived from Cerebrolysin, specifically designed to mimic the neurotrophic effects of the parent compound. It promotes neurogenesis and has shown cognitive-enhancing properties in research.
Full details →MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.
Full details →Side-by-Side Comparison
| Aspect | P21 | MOTS-c |
|---|---|---|
| Mechanism | Inhibits glycogen synthase kinase-3β (GSK-3β) and activates CREB signaling pathway. This promotes BDNF expression, neurogenesis in the hippocampus, and synaptic plasticity. | Activates AMPK pathway, enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and regulates mitochondrial function. Acts as a metabolic hormone affecting whole-body energy homeostasis. |
| Typical Dosage | Research protocols typically use 1-5mg administered intranasally or subcutaneously. Often used in cycles of 2-4 weeks. | Research protocols typically use 5-10mg administered subcutaneously several times per week. Optimal dosing not yet established. |
| Administration | Can be administered intranasally for direct CNS access or subcutaneously. Best used cyclically rather than continuously. | Subcutaneous injection. Often combined with exercise protocols as it enhances exercise capacity and metabolic adaptation. |
| Side Effects | Limited data. Reported effects include mild headache, temporary brain fog during initial use, and fatigue. | Limited human data. Animal studies show good tolerability. May affect energy levels and exercise performance. |
| Best For |